Nothing Special   »   [go: up one dir, main page]

BR112022021640A2 - Usos e formulações de canabinoides - Google Patents

Usos e formulações de canabinoides

Info

Publication number
BR112022021640A2
BR112022021640A2 BR112022021640A BR112022021640A BR112022021640A2 BR 112022021640 A2 BR112022021640 A2 BR 112022021640A2 BR 112022021640 A BR112022021640 A BR 112022021640A BR 112022021640 A BR112022021640 A BR 112022021640A BR 112022021640 A2 BR112022021640 A2 BR 112022021640A2
Authority
BR
Brazil
Prior art keywords
formulations
cannabinoids
covid
patients suffering
cannabidiol
Prior art date
Application number
BR112022021640A
Other languages
English (en)
Inventor
Nowak Reinhard
Nowak Mirko
Jay Nowak Jesko
Pöllinger Norbert
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of BR112022021640A2 publication Critical patent/BR112022021640A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

USOS E FORMULAÇÕES DE CANABINOIDES. A presente invenção refere-se a usos e formulações de canabinoides, em particular de canabidiol. Os canabinoides, em particular o canabidiol, são utilizados para o tratamento de pacientes que sofrem de COVID-19, uma doença provocada pelo coronavírus SARS-Cov-2. As formulações são especialmente para administração oral de canabinoides, em particular de canabidiol. Estas formulações são úteis para o tratamento de pacientes que sofrem de COVID-19.
BR112022021640A 2020-05-11 2020-05-11 Usos e formulações de canabinoides BR112022021640A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/063086 WO2021228365A1 (en) 2020-05-11 2020-05-11 Uses and formulations of cannabinoids

Publications (1)

Publication Number Publication Date
BR112022021640A2 true BR112022021640A2 (pt) 2022-12-13

Family

ID=70861443

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021640A BR112022021640A2 (pt) 2020-05-11 2020-05-11 Usos e formulações de canabinoides

Country Status (11)

Country Link
US (1) US20230181484A1 (pt)
EP (1) EP4149445A1 (pt)
JP (1) JP2023534361A (pt)
CN (1) CN115884759A (pt)
AR (1) AR122059A1 (pt)
AU (1) AU2020447636A1 (pt)
BR (1) BR112022021640A2 (pt)
CA (1) CA3181940A1 (pt)
IL (1) IL298060A (pt)
MX (1) MX2022014199A (pt)
WO (1) WO2021228365A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021247269A1 (en) * 2020-03-29 2022-12-01 Akseera Pharma Corp. Interaction of SARS-CoV-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat Covid-19.
CA3179022A1 (en) * 2020-07-18 2021-10-07 Akseera Pharma Corp. Interaction of sars-cov-2 proteins with molecular and cellular mechanisms of host cells and formulations to treat covid-19
CN111686095A (zh) * 2020-07-24 2020-09-22 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备治疗冠状病毒感染的药物中的用途
WO2023225554A1 (en) * 2022-05-17 2023-11-23 The Regents Of The University Of California Cannabinoids and il-15 activate nk cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
WO2015065179A1 (en) 2013-10-29 2015-05-07 Echo Pharmaceuticals B.V. Compressed tablet containing cannabidiol, method for its manufacture and use of such tablet in oral treatment of psychosis or anxiety disorders
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
CN108697803A (zh) * 2015-10-29 2018-10-23 索卢贝斯特有限公司 透粘膜给药的药物组合物
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
WO2019155337A1 (en) * 2018-02-06 2019-08-15 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and punicalagin and methods of use thereof
CA3108214A1 (en) * 2018-07-18 2020-01-23 Glatt Gmbh Extended release formulations of cannabinoids

Also Published As

Publication number Publication date
WO2021228365A1 (en) 2021-11-18
MX2022014199A (es) 2022-12-06
EP4149445A1 (en) 2023-03-22
AU2020447636A1 (en) 2022-12-08
CN115884759A (zh) 2023-03-31
IL298060A (en) 2023-01-01
JP2023534361A (ja) 2023-08-09
US20230181484A1 (en) 2023-06-15
AR122059A1 (es) 2022-08-10
CA3181940A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
BR112022021640A2 (pt) Usos e formulações de canabinoides
BR112022001413A2 (pt) Preparação de canabidiol, e, método para tratar uma modificação da doença em um paciente que sofre de síndrome de dravet
BR112019001794A2 (pt) composição de cannabis
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
BR0114927A (pt) Composição de gel farmacêutica substancialmente não aquosa para aplicação na pele, e, uso da composição
BRPI0519803A2 (pt) métodos para purificar trans-(-)-delta9-tetraidrocanabinol e trans-(+)-delta9-tetraidrocanabinol
BR112021022139A2 (pt) Preparação de canabidiol, e, método para tratar um paciente que sofre de espasmos epilépticos
BR112019001852A2 (pt) composição de cannabis
BR112017027836A2 (pt) método para o tratamento de inflamação usando compostos naturais e/ou dieta
BR112017007774A2 (pt) Um ou uma combinação dos fitocanabinoides canabidiol (cbd); canabidivarina (cbdv); e tetra- hidrocanabivarina (thcv), combinação dos fitocanabinoides, formulação farmacêutica, e, método para tratamento de um indivíduo que sofre de distrofia muscular de duchenne (dmd).
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
CL2022002564A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
BR112022008000A2 (pt) Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
BR112023019967A2 (pt) Composto de tetra-hidronaftaleno e método de preparação para o mesmo e uso do mesmo em medicina
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
CO2023000130A2 (es) Composición y método para el tratamiento del dolor crónico
BR112023000747A2 (pt) Composições para o tratamento de obesidade
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BRPI0607976A2 (pt) composição farmacêutica e uso de uma composição
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112017025189A2 (pt) composição e usos da mesma
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]